A variety of factors, ranging from consolidation to the emergence of genomics, has helped resurrect clinical labs from near death. The nation's two largest labs, LabCop. and Quest, have seen their stock prices shoot up a staggering 600% in the past three years, while a cadre of more specialized labs has ridden their coattails. These labs are looking to genomics to sustain their renaissance, as existing drivers shift and maintaining their growth rate gets tougher.
By Wendy Diller
At Laboratory Corp. of America 's conference call to discuss first quarter financial results last April the message was firm:...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.
During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn
IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.
